Antibody-Drug Conjugate and T Cell Redirection Advisory Board

John Lambert, PhD
Attager Consulting

John Lambert, Ph.D has been in the antibody-drug conjugate field since joining ImmunoGen in 1987, serving as CSO from 2008-2015. During his tenure with ImmunoGen, the company invented the technology that led to the approved ADCs Kadcyla and Elahere, as well as many other candidates that entered clinical development. He has authored or co-authored over 120 scientific publications.

Anthony Tolcher, MD
NEXT Oncology

Anthony Tolcher, M.D. is a medical oncologist and key opinion leader in the field of developing and running early-stage clinical trials for oncology indications. He is a co-founder of NEXT Oncology and was previously a co-founder of South Texas Accelerated Research Therapeutics (START), both of which are clinical research organizations focused on first-in-human clinical trials. He is dedicated to the development of new anti-cancer agents for patients for whom current cancer therapies are no longer working.